4.4 Review

Allosteric modulators of MEK1: drug design and discovery

Journal

CHEMICAL BIOLOGY & DRUG DESIGN
Volume 88, Issue 4, Pages 485-497

Publisher

WILEY
DOI: 10.1111/cbdd.12780

Keywords

allosteric mechanism; allosteric modulators; cancer treatment; MEK1; signaling pathway

Funding

  1. National Natural Science Foundation of China [81322046, 81302698, 81473137]
  2. Shanghai Rising-Star Program [13QA1402300]
  3. Shanghai Health and Family Planning Commission [20154Y0058]
  4. Natural Science Foundation of Zhejiang Province [LY14H300004]

Ask authors/readers for more resources

Mitogen-activated protein kinase kinase (MAPKK, MEK) mediates signal transduction, controlling cell proliferation and survival. MEK occupies a key downstream position in the Ras-Raf-MEK-ERK signaling pathway, implying that inhibition of MEK will potently suppress tumor cell growth, with potential applications in cancer therapy. Based on the promising therapeutic effects of MEK modulators, continued efforts have been made in this class. Here, we review the discovery and development of MEK1 allosteric modulators, classifying them into four structural groups. The allosteric mechanisms and recent clinical progress involving these modulators are also reviewed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available